A study finds that the antiviral drug is safe to prescribe in children with COVID-19 who are at least 6 years old.

Paxlovid safe for children age 6 and up, new data reveal

An antiviral drug approved in Japan to treat COVID-19 can be effective post-exposure prophylaxis, too.

Newly Approved Xocova Cuts SARS-CoV-2 Transmission To Household Contacts

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.    Medscape Medical News

Pfizer Trial Backs Paxlovid Dose for High-Risk Children

Pfizer’s oral COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) and Novo Nordisk Pharma’s once-weekly basal insulin Awiqli (insulin icodec) are set for NHI price reductions in Japan under the cost-effectiveness assessment (CEA) scheme.

Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs

HKUMed–Tsinghua team develops first-in-class broad-spectrum small-molecule antiviral to combat SARS-CoV-2 and related coronaviruses

antiviral news

Press Releases in the global landscape